Expression profiles of mTOR pathway proteins in porocarcinoma: A provisional immunohistochemical study
- Authors:
- Mitsuaki Ishida
- Hidetoshi Okabe
View Affiliations
Affiliations: Department of Clinical Laboratory Medicine and Division of Diagnostic Pathology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan
- Published online on: October 11, 2012 https://doi.org/10.3892/br.2012.20
-
Pages:
28-30
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Porocarcinoma is a rare skin appendage carcinoma, with a poor prognosis. At present, the recommended treatment of localized porocarcinoma is wide surgical resection. Although anthracyclin‑based chemotherapy or combination of 5‑fluorouracil (5-FU), taxanes and cisplatin are considered to be the first‑line treatment for metastatic or locally‑advanced porocarcinoma, this type of tumor is recognized as relatively chemoresistant, and no standard systemic treatment has been established yet. Mammalian target of rapamycin (mTOR) is an important protein involved in carcinogenesis. mTOR phosphorylates the eukaryotic translation initiation factor 4E-binding protein 1 (4E‑BP1), and then phosphorylated 4E‑BP1 (p4E-BP1) triggers cell cycle progression, cell proliferation and angiogenesis. Therefore, mTOR is believed to be one of the most promising therapeutic targets in various types of carcinomas. However, the expression profiles of mTOR pathway proteins in porocarcinoma have yet to be elucidated. Therefore, we analyzed the expression of mTOR, 4E-BP1 and p4E-BP1 in five cases of porocarcinoma (four invasive and one in situ case) using immunohistochemical methods. mTOR expression was observed in the invasive porocarcinoma cases, but not in the in situ case. 4E-BP1 was expressed in all five cases. p4E-BP1 expression was observed in 3/4 invasive porocarcinoma cases, but not in the in situ case. This preliminary study clearly demonstrated the overexpression of mTOR and its downstream proteins in most of the included invasive porocarcinoma cases. Therefore, mTOR inhibitors could be considered as potential therapeutic modalities for the treatment of metastatic or locally‑advanced porocarcinoma.
View References
|
1.
|
Mehregan AH, Hashimoto K and Rahbari H:
Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch
Dermatol. 119:104–114. 1992. View Article : Google Scholar
|
|
2.
|
Snow SN and Reizner GT: Eccrine
porocarcinoma of the face. J Am Acad Dermatol. 27:306–311. 1992.
View Article : Google Scholar
|
|
3.
|
Ishida M, Hotta M, Kushima R and Okabe H:
A case of porocarcinoma arising in pigmented hidroacanthoma simplex
with multiple lymph node, liver and bone metastases. J Cutan
Pathol. 38:227–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Perez-Garcia J, Morales R, Valverde CM, et
al: Eccrine porocarcinoma presenting with scrotal lymphedema: a
case report and review of systemic treatment. Ann Oncol.
21:9072010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Faivre S, Kroemer G and Raymond E: Current
development of mTOR inhibitors as anticancer agents. Nat Rev Drug
Discov. 5:671–688. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Yao JC, Shah MH, Ito T, et al: Everolimus
for advanced pancreatic neuroendocrine tumors. N Engl J Med.
364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Duran I, Kortmansky J, Singh D, et al: A
phase II clinical and pharmacodynamic study of temsirolimus in
advanced neuroendocrine carcinomas. Br J Cancer. 96:1148–1154.
2006. View Article : Google Scholar
|
|
8.
|
Darb-Esfahani S, Faggad A, Noske A, et al:
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma:
association with stage and grade in vivo and link with response to
rapamycin treatment in vitro. J Cancer Res Clin Oncol. 135:933–941.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chen S, Nakahara T, Uchi H, et al:
Immunohistochemical analysis of the mammalian target of rapamycin
signaling pathway in extramammary Paget’s disease. Br J Dermatol.
161:357–363. 2009.
|
|
10.
|
Gao N, Flynn DC, Zhang Z, et al: G1 cell
cycle progression and the expression of G1 cyclins are regulated by
PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J
Physiol Cell Physiol. 287:C281–C291. 2004. View Article : Google Scholar : PubMed/NCBI
|
